Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is entering Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

Custirsen utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to target and inhibit production of clusterin. OncoGenex and Isis partnered in the successful discovery and initial development of custirsen. Teva and OncoGenex are responsible for the development and commercialization of custirsen, subject to their global collaboration and license agreement and subject to OncoGenex's financial obligations to Isis. Key intellectual property related to custirsen, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... California (PRWEB) October 23, 2014 ... a specialty pharmaceutical company devoted to bringing new ... partnerships in 2015. , ViaDerma has developed an ... allows for rapid mass transfer of pharmaceutical active ... body to provide immediate localized therapy. The transdermal ...
(Date:10/25/2014)... This research report “Biodegradable Plastics Market ... Regenerated Cellulose, PCL), by Application (Packaging, Fibers, Agriculture, ... 2019”, defines and segments the global biodegradable plastics ... global volume and value. , Browse 75 Market ... Slides and in-depth TOC on “Biodegradable Plastics Market ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... October 24, 2014 ... ) has announced the addition of the  ... And Other 2-D Nanomaterials "  report to ... , ,CNTs and graphene are the strongest, ... man, with a performance-per-weight greater than any ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
... , EMERYVILLE, Calif. , ... today announced that it will present at the 12th Annual BIO ... at 8:30 a.m. Eastern Time ( 5:30 a.m. Pacific ... presentation on our website at: , http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , ...
... ... 20 Years of Experience to Biochemical Innovator, , ... Houston, TX (PRWEB) February 2, 2010 ... microbiology innovations that produce green chemicals, today announced the appointment of Daniel J. ...
... , SANTA ROSA, Calif. ... Month, EcoNugenics introduces the newest in ... Santa Rosa, CA -based nutraceutical company, founded in 1995 by integrative ... MS, LAc, has once again demonstrated excellence in being at the forefront ...
Cached Biology Technology:Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 2Glycos Biotechnologies Expands Management Team with Appointment of Vice President of Research and Development 2Glycos Biotechnologies Expands Management Team with Appointment of Vice President of Research and Development 3Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3
(Date:10/16/2014)... 16, 2014) – Post-menopausal women experienced improvements in ... levels or genital bleeding, after 12 weeks of ... fermented soy germ-based nutritional supplement previously shown to ... new peer-reviewed pilot study reported in a poster ... scientific meeting. , "These data documented improved ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... Ebola virus is spreading rapidly and to an unexpected ... in the past and the virus shows a new ... recorded before. For this reason, the German National Academy ... Science and Engineering, and the Union of the German ... on the Ebola epidemic today. , In the statement ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... has brought powerful software to the never-ending arms race ... biochemists have developed and laboratory-tested a computer program that ... bacteria use to make natural antibiotics. ... as the algorithm "K*" (pronounced K Star)-- is able ...
... University researchers want to strengthen chemistry skills starting ... ways for high school- and college-level educators to ... Melanie Cooper and Gautam Bhattacharyya, along with Michael ... molecular, cellular and developmental biology at the University ...
... of a symposium on "Defining species for threatened ... Service, will discuss the need to explicitly consider ... concepts continue to be a contentious, but largely ... between groups of organisms are identified, however, can ...
Cached Biology News:Duke software dramatically speeds enzyme design 2Duke software dramatically speeds enzyme design 3Clemson chemists present revolutionary teaching concepts 2Dealing with taxonomic uncertainty for threatened and endangered species 2
... (RNase-free) (E.C. 3.1.21.1) is a nonspecific endonuclease ... It functions by hydrolyzing phosphodiester linkages, producing ... a 3'-hydroxyl group. Ambion's RNase-free DNase I ... is recommended to degrade DNA in the ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
... a unique β-agarose digesting enzyme developed at ... DNA and RNA from low melting point ... TBE, MOPS, or phosphate buffers. The gel ... TBE, MOPS, and phosphate electrophoresis buffers or ...
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
Biology Products: